Michael J Fox Foundation

Michael J. Fox Foundation, 23andMe collaborate

Tuesday, October 31, 2017

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 23andMe announced a collaboration to build a large, diverse cohort of both patients and control volunteers who have consented to participate in research. This cohort will provide researchers, drug makers, regulators and payers critical insight into the lived experience, genetics and variability of Parkinson’s disease. The study, Fox Insight (foxinsight.org), is open to anyone 18 or older worldwide with or without Parkinson’s disease and aims to recruit tens or even hundreds of thousands of patients to contribute data.

[Read More]

Mitochon Pharmaceuticals to support mitochondrial research in Parkinson’s

Wednesday, October 4, 2017

Mitochon Pharmaceuticals announced that it was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help develop its mitochondrial targeted compounds for treating Parkinson’s disease. The funding will go to pivotal animal studies to assess the benefits of Mitochon’s compounds in ameliorating the deficits associated with dopaminergic neuron loss, the hallmark of Parkinson’s disease. If successful, Mitochon’s compounds, MP101 ad MP201 could be in patients as early as 2019.

[Read More]

Three Questions: John Moore, Trialogics

Monday, July 24, 2017

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Suz Redfearn spoke with John Moore, formerly a venture capitalist in the technology space, now executive chairman of Trialogics, a provider of clinical trial software serving biotech and pharma partners.

[Read More]

MJFF promotes Sohini Chowdhury to deputy CEO

Thursday, April 20, 2017

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the promotion of Sohini Chowdhury to the role of deputy chief executive officer. In her previous capacity as senior vice president, Research Partnerships, Chowdhury was instrumental in driving the Foundation’s innovative alliances with key Parkinson’s research stakeholders for the benefit of the estimated five million people worldwide living with Parkinson’s disease.

[Read More]

Keapstone Therapeutics created as new virtual biotech for Parkinson’s

Monday, March 20, 2017

The University of Sheffield and Parkinson’s UK have combined forces to create Keapstone Therapeutics. The goal of the newly formed company is to help move research into nuclear factor erythroid 2-related factor 2 (Nrf2) through the development process and, hopefully, into testable treatments for Parkinson’s disease. Parkinson’s disease affects around 1 million people in the U.S. and 127,000 in the U.K.

[Read More]

Neuropore Therapies awarded Parkinson’s research grant from Michael J. Fox Foundation

Tuesday, January 31, 2017

Neuropore Therapies, a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders, has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

[Read More]

Recursion wins award for drug discovery platform

Monday, December 26, 2016

Recursion Pharmaceuticals announced that it has won two Fierce Innovation awards from the biotech and pharmaceutical industries today for its innovative platform. The awards, “Best Biotech Innovation” and “Best In Show—New Product or Service,” recognize Recursion’s disruptive combination of experimental biology and artificial intelligence applied to drug discovery.

[Read More]

Wearables track drug effectiveness in Parkinson’s patients

Monday, January 18, 2016

Cynapsus and the Michael J. Fox Foundation (MJFF) are partnering to incorporate a wearable device into a phase III study of patients with Parkinson’s disease. Similar to a smartwatch, the device is equipped with motion sensors to detect when patients have an “OFF” episode—a period where medicine stops working and motor impairment symptoms return. The symptoms include muscle stiffness or problems with starting movements, such as starting to walk or getting out of a chair.

[Read More]